Parkin regulates IGF2BP3 through ubiquitination in the tumourigenesis of cervical cancer.

Publisher: Wiley Country of Publication: United States NLM ID: 101597971 Publication Model: Print Cited Medium: Internet ISSN: 2001-1326 (Electronic) Linking ISSN: 20011326 NLM ISO Abbreviation: Clin Transl Med Subsets: MEDLINE

Publication: 2020- : [Hoboken, NJ] : Wiley
Original Publication: Heidelberg : Springer-Verlag

Phosphatidylinositol 3-Kinases*/metabolism ; Ubiquitin-Protein Ligases*/genetics ; Ubiquitin-Protein Ligases*/metabolism ; Uterine Cervical Neoplasms*/genetics ; RNA-Binding Proteins*/genetics; Animals ; Female ; Humans ; Mice ; Carcinogenesis/genetics ; Ubiquitination/genetics

Background: Insulin-like growth Factor 2 mRNA-binding protein 3 (IGF2BP3) is a highly conserved RNA-binding protein and plays a critical role in regulating posttranscriptional modifications.
Methods: Immunoprecipitation was used to examine the interaction of Parkin and IGF2BP3. Mass spectrometry was performed to identify the ubiquitination sites of IGF2BP3. RNA-immunoprecipitation was conducted to examine the target genes of IGF2BP3. Xenograft mouse model was constructed to determine the tumorigenesis of IGF2BP3.
Results: IGF2BP3 expression is negatively correlated with Parkin expression in human cervical cancer cells and tissues. Parkin directly interacts with IGF2BP3, and overexpression of Parkin causes the proteasomal degradation of IGF2BP3, while knockdown of PARK2 increases the protein levels of IGF2BP3. Mechanistically, in vivo and in vitro ubiquitination assays demonstrated that Parkin is able to ubiquitinate IGF2BP3. Moreover, the ubiquitination site of IGF2BP3 was identified at K213 in the first KH domain of IGF2BP3. IGF2BP3 mutation results in the loss of its oncogenic function as an m6A reader, resulting in the inactivation of the phosphoinositide 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) signalling pathways. In addition, IGF2BP3 mutation results in the attenuation of Parkin-mediated mitophagy, indicating its inverse role in regulating Parkin. Consequently, the tumourigenesis of cervical cancer is also inhibited by IGF2BP3 mutation.
Conclusion: IGF2BP3 is ubiquitinated and regulated by the E3 ubiquitin ligase Parkin in human cervical cancer and ubiquitination modification plays an important role in modulating IGF2BP3 function. Thus, understanding the role of IGF2BP3 in tumourigenesis could provide new insights into cervical cancer therapy.
(© 2023 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.)

Nature. 2005 Nov 24;438(7067):512-5. (PMID: 16306994)
JAMA. 2018 Mar 13;319(10):1058. (PMID: 29536098)
Annu Rev Biochem. 2013;82:387-414. (PMID: 23495935)
Cell Signal. 2021 Apr;80:109912. (PMID: 33388443)
Oncogene. 2017 Mar;36(10):1315-1327. (PMID: 27593930)
J Biol Chem. 2011 Jul 22;286(29):25882-90. (PMID: 21613208)
Clin Transl Med. 2023 Oct;13(10):e1457. (PMID: 37877353)
Oncotarget. 2017 Jun 20;8(25):40469-40485. (PMID: 28465487)
Cancer Commun (Lond). 2018 Jun 26;38(1):40. (PMID: 29941042)
Cancer Res. 2021 Feb 15;81(4):923-934. (PMID: 33293428)
Elife. 2021 Nov 15;10:. (PMID: 34779401)
Genes Dev. 2013 Feb 1;27(3):301-12. (PMID: 23388827)
Cancer Cell Int. 2021 Dec 4;21(1):647. (PMID: 34863153)
Cells. 2019 Jun 21;8(6):. (PMID: 31234354)
Curr Pharm Des. 2020;26(32):3939-3954. (PMID: 32282295)
J Cell Biol. 2003 Jan 6;160(1):77-87. (PMID: 12507992)
Science. 2007 Mar 16;315(5818):1576-9. (PMID: 17322030)
Mol Cancer. 2017 Apr 11;16(1):77. (PMID: 28399871)
Nat Rev Cancer. 2006 May;6(5):369-81. (PMID: 16633365)
Mol Cell Biol. 1999 Feb;19(2):1262-70. (PMID: 9891060)
J Clin Invest. 2013 Jul;123(7):2832-49. (PMID: 23921128)
Genes Dev. 2016 Nov 15;30(22):2459-2474. (PMID: 27940961)
J Biol Chem. 2011 Sep 9;286(36):31145-52. (PMID: 21757716)
Nucleic Acids Res. 2004 Aug 16;32(14):4368-76. (PMID: 15314207)
Curr Opin Cell Biol. 2015 Apr;33:95-101. (PMID: 25697963)
Oncogene. 2012 Nov 1;31(44):4689-97. (PMID: 22266872)
Hepatology. 2008 Oct;48(4):1118-27. (PMID: 18802962)
Mol Cancer. 2022 Feb 23;21(1):60. (PMID: 35197058)
Cell Death Discov. 2022 Feb 8;8(1):53. (PMID: 35136045)
Am J Surg Pathol. 2011 Nov;35(11):1638-45. (PMID: 21997684)
Am J Transl Res. 2021 Feb 15;13(2):480-496. (PMID: 33594305)
Hum Pathol. 2014 Nov;45(11):2218-24. (PMID: 25176620)
Cell. 2010 Apr 2;141(1):129-41. (PMID: 20371350)
PLoS One. 2012;7(11):e50621. (PMID: 23226335)
Adv Sci (Weinh). 2021 Jan 29;8(6):2002831. (PMID: 33747724)
EMBO Rep. 2015 May;16(5):618-27. (PMID: 25739811)
Proc Natl Acad Sci U S A. 2017 Feb 28;114(9):2307-2312. (PMID: 28193878)
Biochem Biophys Res Commun. 2020 Aug 13;529(1):43-50. (PMID: 32560817)
Cell Mol Life Sci. 2013 Aug;70(15):2657-75. (PMID: 23069990)
Nat Cell Biol. 2018 Mar;20(3):285-295. (PMID: 29476152)
J Clin Oncol. 2013 Mar 20;31(9):1231-8. (PMID: 23358974)
Acta Neuropathol. 2018 Feb;135(2):227-247. (PMID: 29134320)
Acta Pharm Sin B. 2022 Feb;12(2):838-852. (PMID: 35256949)
Circ Res. 2012 Oct 12;111(9):1208-21. (PMID: 23065344)
Cell Death Dis. 2019 Mar 8;10(3):232. (PMID: 30850585)

Keywords: IGF2BP3; cervical cancer; mitophagy; parkin; ubiquitination

EC 2.7.1.- (Phosphatidylinositol 3-Kinases)
EC 2.3.2.27 (Ubiquitin-Protein Ligases)
EC 2.3.2.27 (parkin protein)
0 (IGF2BP3 protein, human)
0 (RNA-Binding Proteins)

Date Created: 20231025 Date Completed: 20231030 Latest Revision: 20231101

20240628

PMC10599278

10.1002/ctm2.1457

37877353